POU2F3 antibody - N-terminal region (ARP32537_P050)
- Known as:
- POU2F3 (anti-) - N-terminal region (ARP32537_P050)
- Catalog number:
- arp32537_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- POU2F3 antibody - N-terminal region (ARP32537_P050)
Related genes to: POU2F3 antibody - N-terminal region (ARP32537_P050)
- Gene:
- POU2F3 NIH gene
- Name:
- POU class 2 homeobox 3
- Previous symbol:
- -
- Synonyms:
- OCT11, PLA-1, Skn-1a, Epoc-1
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-11-28
- Date modifiied:
- 2014-11-19
Related products to: POU2F3 antibody - N-terminal region (ARP32537_P050)
Related articles to: POU2F3 antibody - N-terminal region (ARP32537_P050)
- Although small cell lung cancer (SCLC) comprises transcription factor (TF)-defined molecular subtypes (ASCL1, NEUROD1, POU2F3), the extent to which these subtypes predict response to clinically effective therapy in patients-and whether therapy can select for subtype switching-remains unknown. The recent approval of the DLL3×CD3 bispecific T-cell engager tarlatamab represents one of the first meaningful advances in relapsed small cell lung cancer (SCLC) in decades, yet responses remain heterogeneous and resistance is inevitable. Here, we inferred SCLC gene expression from circulating chromatin in prospectively collected patient plasma (46 patients; 167 samples), enabling interrogation of response and acquired resistance to tarlatamab. Parallel development of the first immunocompetent syngeneic mouse model to study tarlatamab response and resistance enabled functional validation. Across species, findings converged on a central principle: TF subtype governs both initial response and acquired resistance. Therapeutic response was significantly associated with ASCL1-subtype tumors, whereas NEUROD1-subtype tumors exhibited inferior responses and POU2F3-subtype tumors were uniformly resistant, consistent with DLL3 being a direct ASCL1 transcriptional target and most highly expressed in ASCL1-positive tumors. Strikingly, one mode of acquired resistance revealed therapeutic selection for a NEUROD1-high state with concomitant DLL3 downregulation. Other resistant tumors exhibited enrichment of regulatory and exhausted T-cell programs, highlighting tarlatamab's dual-targeting mechanism of action. Together, these results reveal that tarlatamab exerts selective pressure against ASCL1-driven lineages, facilitating resistance through loss of an antigen intrinsically linked to that state. These findings underscore the clinical relevance of TF-defined molecular subtypes in human SCLC. More broadly, they highlight the power of integrating longitudinal plasma transcriptional profiling from patient plasma with functional mouse modeling to uncover clinical and biological mechanisms of response and resistance to cell-surface-targeted therapies. - Source: PubMed
Publication date: 2026/04/08
Vasseur DamienSaito ShinGulati Gunsagar SLee Garyoung GaryLaimon Yasmin NSimsek BerkayLerner MaddieCho HyeonseoLi YixiangWang TianchuSeo Ji-HeuiSavignano HunterJames BradyZhang ZeSemaan KarlJin ZhenjieDaoud Khatoun WassimNafeh GaelleNawfal RashadCooper Alissa JMiller KathrynSeager Maxwell DBrea Elliott JSmith EricChang JonathanPelletier MarcCosta CarlottaChoueiri Toni KSignoretti SabinaSands JacobBaca Sylvan CFreedman Matthew LOser Matthew G - Tuft cells (TCs) are rare chemosensory epithelial cells that regulate mucosal homeostasis in multiple organs, but their role in salivary gland (SG) biology remains poorly defined. This study aimed to define TC structure in mice submandibular glands (SMGs), determine how TC loss affects gland organization and function, and evaluate whether TC abundance in human minor SGs is associated with Sjögren's disease (SjD) features. Specifically, TC ultrastructure and ductal localization were characterized in female and male C57BL/6J mouse SMGs by transmission electron microscopy and immunostaining. Wild-type and C57BL/6J- (TC-deficient mouse strain) SMGs were analyzed by histology and bulk RNA-seq, and salivary function was assessed by saliva flow and proteomics. Human minor SG biopsies from SjD and non-Sjögren sicca (nSjD) patients were analyzed by immunostaining and Poisson regression. In mice SMGs, TCs showed conserved ultrastructural features and localization in both sexes. TC loss was associated with marked sex-biased transcriptome remodeling, morphological disruption, and altered saliva quantity and quality. In humans, TC counts differed between nSjD and SjD groups and were associated with salivary flow, serologic status, and histopathologic features. These findings support a role for TCs in SG epithelial integrity and suggest TC abundance as a candidate biomarker of SG dysfunction. - Source: PubMed
Publication date: 2026/03/25
Rusiniak Michael EShimagami LaraDrumond Victor ZanettiSouza Mariana SilveiraCastro Fernanda Luiza Araujo Lima deXue ChaoZhang MingQu JunChlipala George EdwardMaienschein-Cline MarkSilva Tarcilia Aparecida daSousa Silvia Ferreira deDos Santos Harim Tavares - - Source: PubMed
Publication date: 2026/04/07
Bomidi CarolynWang LuqiongNguyen-Phuc HoaEstes Mary KBlutt Sarah E - POU2F3 is a newly identified immunohistochemical marker specific for the chemosensory tuft cells-related subtype of small cell lung carcinoma (SCLC-P). The characteristics of SCLC-P remain incompletely defined, and POU2F3 expression patterns across different organs and tissue types are poorly documented. - Source: PubMed
Publication date: 2026/04/07
Chen XiaoyanZou FangfangXu HaiminZhang ZhihanWang JingLi YueJia JingdanSun ShanshanWang ChaofuZhang Jing - An increasing number of studies have shown that ferroptosis is related to the initiation and development of small cell lung cancer (SCLC). The systematic review aimed to summarize the characteristics of ferroptosis from its pathogenetic role to translational therapeutic implications in SCLC. - Source: PubMed
Publication date: 2026/03/23
Coradduzza DonatellaLa Salvia AnnaFanciulli GiuseppeDe Miglio Maria Rosaria